Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX ®

Condition:   Prostate Cancer Interventions:   Drug: LY01005;   Drug: ZOLADEX® 3.6 mg Sponsor:   Luye Pharma Group Ltd. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials